Differential serostatus of Epstein-Barr virus in Iranian MS patients with various clinical patterns

Area of Science:

• Immunology
• Neuroscience
• Virology

Background:

• Epidemiological studies indicate a potential link between Epstein-Barr virus (EBV) infection and the development of Multiple Sclerosis (MS).
• Investigating EBV-specific immune responses in MS patients is crucial for understanding disease pathogenesis.

Purpose of the Study:

• To quantify EBV-specific antibodies (EBNA-1 IgG, VCA IgG) in MS patients across different clinical subtypes (RRMS, SPMS, PPMS) and healthy controls.
• To assess the association between EBV antibodies and the production of key cytokines (IFN-γ, IL-12, IL-4) in MS patients.
• To compare these immune markers between MS subtypes and healthy individuals.

Main Methods:

• Enzyme-Linked Immunosorbent Assay (ELISA) was employed to measure EBNA-1 IgG and VCA IgG antibody titers.
• Cytokine levels (IFN-γ, IL-12, IL-4) were quantified using ELISA in serum samples.
• Patients were categorized into Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), and Primary Progressive MS (PPMS) groups.

Main Results:

• MS patients exhibited significantly higher titers of anti-EBV antibodies compared to healthy controls.
• SPMS patients showed elevated EBNA-1 IgG levels, while RRMS patients had higher VCA IgG levels compared to PPMS.
• PPMS patients displayed increased IFN-γ and IL-12, with decreased IL-4, compared to other MS subtypes. Higher anti-EBV antibodies correlated with increased IL-12 in RRMS patients.

Conclusions:

• EBV infection is strongly implicated as a risk factor in the pathogenesis of Multiple Sclerosis.
• Monitoring EBV antibody levels could aid in risk assessment for MS, particularly across its clinical subtypes.
• Targeting EBV-related factors may offer therapeutic strategies to reduce MS incidence and disease progression.